Renasant Corporation
NYSE:RNSTBanks - Regional
+$0.46 today
- Market cap
- $3.58B
- Beta
- 0.99
- P/E (TTM)
- 17.1
- EPS (TTM)
- $2.43
- Dividend yield
- 2.21%
Volume 0.75M
Average 0.69M
RNST Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Renasant CorporationNYSE: RNST
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How RNST compares with its peers on the latest reported figures
- RNST's LTM Sep 2026 research & development of $0 is the 2nd highest of the 11 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for RNST, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $47.52M | — | — | 1.1% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RNST) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for RNST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 695.67M | 691.06M | 909.77M | 1.04B | 1.44B |
| Cost of Revenue | 42.52M | 84.38M | 293.59M | 384.85M | 565.75M |
| Gross Profit | 653.15M | 606.68M | 616.19M | 653.18M | 878.39M |
| Gross Margin | 93.9% | 87.8% | 67.7% | 62.9% | 60.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 292.83M | 275.98M | 296.49M | 299.98M | 386.92M |
| Operating Expenses | 430.33M | 395.37M | 439M | 408.21M | 651.66M |
| Depreciation & Amortization | 47.35M | 42.74M | 35.23M | 32.28M | 16.21M |
| EBITDA | 270.18M | 254.05M | 212.42M | 277.25M | 242.94M |
| EBITDA Margin | 38.8% | 36.8% | 23.3% | 26.7% | 16.8% |
| Operating Income | 222.83M | 211.31M | 177.19M | 244.97M | 226.73M |
| Operating Margin | 32.0% | 30.6% | 19.5% | 23.6% | 15.7% |
| Interest Income | 468.69M | 541.81M | 797.32M | 887.78M | 1.26B |
| Interest Expense | 44.68M | 60.51M | 277.99M | 375.58M | 458.29M |
| Other Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax | 222.83M | 211.31M | 177.19M | 244.97M | 226.73M |
| Pre-Tax Margin | 32.0% | 30.6% | 19.5% | 23.6% | 15.7% |
| Income Tax Expense | 46.94M | 45.24M | 32.51M | 49.51M | 45.46M |
| Net Income | 175.89M | 166.07M | 144.68M | 195.46M | 181.27M |
| Net Margin | 25.3% | 24.0% | 15.9% | 18.8% | 12.6% |
| EPS (Basic) | 3.13 | 2.97 | 2.58 | 3.29 | 2.09 |
| EPS (Diluted) | 3.12 | 2.95 | 2.58 | 3.27 | 2.07 |
| Weighted Avg Shares | 56.11M | 55.9M | 56.14M | 59.35M | 94.47M |
| Weighted Avg Shares (Diluted) | 56.42M | 56.21M | 56.14M | 59.75M | 95.17M |
Renasant Corporation
NYSE:RNST
Intrinsic Alpha fair value
Locked
Current Price
$39.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.